Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits.
To clarify whether intravesical usage of fibrin clot stabilizer epsilon-aminocaproic acid (EACA) or p-aminomethyl benzoic acid (PAMBA) and different injuries enhance fibronectin (FN)-mediated bacillus Calmette-Guérin (BCG) attachment to bladder wall. Thirty New Zealand male white rabbits were randomly divided into five groups and the bladder wall of each rabbit was injured by electrocautery, cryocautery or knife cutting on left lateral wall, right lateral wall and posterior wall in different groups, respectively. Different drug was instilled into the bladder: Group A: pure PBS; B: PBS and radiolabeled BCG ((3)H-BCG); C: EACA and (3)H-BCG; D: PAMBA and (3)H-BCG; E: heparin and (3)H-BCG. After instillation, each injured and non-injured bladder wall were surgically harvested and digested. The quantity of BCG attachment was detected by liquid scintillation counter (scintillation times per min, STPM). Quantity of BCG attachment to injured bladder wall was significantly (P < 0.01) greater than that of non-injured one, no matter which injury was performed. The BCG attachment to bladder wall in Group C or Group D was significantly (P < 0.05) greater than that of Group B. The quantity of BCG attachment to bladder of Group E was significantly (P < 0.05) less than that of Group B, C and D, respectively. Intravesical instillation of fibrin clot stabilizer (PAMBA, EACA) enhances FN-mediated BCG attachment to bladder wall while heparin inhibits this process. Injuries; e.g., cutting, cryocautery or electrocautery of bladder wall can significantly increase BCG attachment to the bladder wall.
Shen
Zhou-Jun
ZJ
Department of Urology, Rui Jin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, PR China. shenzhj@mail.hz.zj.cn
Wang
Yi
Y
Ding
Guo-Qing
GQ
Pan
Chun-Wu
CW
Zheng
Rong-Ming
RM
D010129:4-Aminobenzoic Acid / Q000494:pharmacology; D000283:Administration, Intravesical; D015119:Aminocaproic Acid / Q000494:pharmacology; D000818:Animals; D000933:Antifibrinolytic Agents / Q000494:pharmacology; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D004195:Disease Models, Animal; D005343:Fibrinolytic Agents / Q000494:pharmacology; D005353:Fibronectins / Q000502:physiology; D006493:Heparin / Q000494:pharmacology; D008297:Male; D009163:Mycobacterium bovis / Q000187:drug effects / Q000502:physiology*; D011817:Rabbits; D001743:Urinary Bladder / Q000382:microbiology* / Q000503:physiopathology; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D062366:para-Aminobenzoates
D000933:Antifibrinolytic Agents; D005343:Fibrinolytic Agents; D005353:Fibronectins; D062366:para-Aminobenzoates; C015668:4-aminomethylbenzoic acid; D006493:Heparin; D010129:4-Aminobenzoic Acid; D015119:Aminocaproic Acid